Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. (Q36812982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Tai-Tsang Chen

1 reference

16 August 2017

language of work or name

English

0 references

publication date

25 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

18 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Nivolumab in previously untreated melanoma without BRAF mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Statistical issues and challenges in immuno-oncology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Nivolumab plus ipilimumab in advanced melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

The blockade of immune checkpoints in cancer immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

New challenges in endpoints for drug development in advanced melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Improved Endpoints for Cancer Immunotherapy Trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Immunostimulatory monoclonal antibodies for cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

A Multiple Testing Procedure for Clinical Trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Analysis of survival by tumor response.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Cancer immunotherapy advances spawn calls for new endpoints

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4836810

AACR Cancer Progress Report 2013.

5 September 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV156

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV156

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV156

Discrete sequential boundaries for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV156

Analyzing survival curves at a fixed point in time

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26113579

12 December 2020

inferred from PubMed ID database lookup

Repeated assessment of results in clinical trials of cancer treatment

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26113579

12 December 2020

inferred from PubMed ID database lookup

The Hazards of Endpoints

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26113579

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1093/JNCI/DJV156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

release_dj3lsvjcr5ey3ogyg6xne2ipfq

18 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dj3lsvjcr5ey3ogyg6xne2ipfq

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

PubMed publication ID

26113579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113579%20AND%20SRC:MED&resulttype=core&format=json